New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.54
5.03
+1.77%
Follow ABBV
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $24.25 was left as profit. Gross margin has risen two quarters running, from 71.9% to 75.4%. What is an income statement?
| Revenue | 17.4 | 100.0% |
|---|---|---|
| Cost of revenue | −4.3 | −24.6% |
| Gross profit | 13.1 | 75.4% |
| Research & development | −2.6 | −14.7% |
| Selling, general & admin | −4.1 | −23.5% |
| Other operating costs | −0.2 | −1.1% |
| Operating income | 6.3 | 36.0% |
| Other income, net | −1.4 | −8.3% |
| Income tax | −0.6 | −3.5% |
| Net income | 4.2 | 24.2% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $16.6B | $15.0B | $17.0B | $17.4B |
| Operating income | $4.5B | $4.0B | $6.4B | $6.3B |
| Net income | $1.8B | $697M | $3.6B | $4.2B |
| Net margin (right axis) | 10.9% | 4.6% | 21.3% | 24.2% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
17,404.00 | 16,990.00 | 15,002.00 | 16,618.00 |
+8 more quarters Free account |
Revenue Growth |
10.32% | 10.16% | 12.43% | 10.04% | |
Cost of Revenue |
4,285.00 | 4,291.00 | 4,218.00 | 4,552.00 | |
Gross Profit |
13,119.00 | 12,699.00 | 10,784.00 | 12,066.00 | |
R&D Expenses |
2,567.00 | 2,344.00 | 2,472.00 | 2,579.00 | |
SG&A Expenses |
4,087.00 | 3,632.00 | 3,578.00 | 3,895.00 | |
Operating Income |
6,267.00 | 6,432.00 | 3,990.00 | 4,544.00 | |
Non-operating Interest Expenses |
700.00 | 679.00 | 645.00 | 655.00 | |
Non-operating Income/Expense |
(1,438.00) | (2,154.00) | (2,951.00) | (1,876.00) | |
| 4,829.00 | 4,278.00 | 1,039.00 | 2,668.00 | ||
Income Tax Provision |
609.00 | 662.00 | 342.00 | 853.00 | |
Income after Tax |
4,220.00 | 3,616.00 | 697.00 | 1,815.00 | |
Dividends (Preferred) |
— | — | 10.00 | 30.00 | |
Non-Controlling Interest |
2.00 | 3.00 | 2.00 | (1.00) | |
Net Income Common |
4,218.00 | 3,613.00 | 685.00 | 1,786.00 | |
EPS (Basic) |
2.37 | 2.03 | 0.39 | 1.02 | |
EPS (Diluted) |
2.37 | 2.03 | 0.39 | 1.02 | |
Shares (Basic, Weighted) |
1,769.00 | 1,769.00 | 1,770.00 | 1,769.00 | |
Shares (Diluted, Weighted) |
1,772.00 | 1,771.00 | 1,774.00 | 1,773.00 | |
Gross Margin |
75.38% | 74.74% | 71.88% | 72.61% | |
EBIT Margin |
36.01% | 37.86% | 26.60% | 27.34% | |
EBT margin |
27.75% | 25.18% | 6.93% | 16.05% | |
Net Profit Margin |
24.24% | 21.27% | 4.57% | 10.75% | |
EBITDA |
8,128.00 | 8,315.00 | 5,926.00 | 6,531.00 | |
EBIT |
6,267.00 | 6,432.00 | 3,990.00 | 4,544.00 | |
Income from Continuous Operations |
4,220.00 | 3,616.00 | 697.00 | 1,815.00 | |
Consolidated Net Income/Loss |
4,220.00 | 3,616.00 | 697.00 | 1,815.00 | |
EPS (Basic, from Continuous Ops) |
2.39 | 2.04 | 0.39 | 1.03 | |
EPS (Diluted, from Cont. Ops) |
2.38 | 2.04 | 0.39 | 1.02 | |
EPS (Basic, Consolidated) |
2.39 | 2.04 | 0.39 | 1.03 | |
EPS (Diluted, Consolidated) |
2.38 | 2.04 | 0.39 | 1.02 | |
Shares (Diluted, Average) |
1,772.00 | 1,771.00 | 1,774.00 | 1,774.00 | |
EBITDA Margin |
46.70% | 48.94% | 39.50% | 39.30% | |
Operating Cash Flow Margin |
43.70% | 20.22% | 25.52% | 31.40% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026